| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 72,720 | 60,204 | ||
| General and administrative expenses | 327,177 | 341,199 | ||
| Total operating expenses | 399,897 | 401,403 | ||
| Loss from operations | -399,897 | -401,403 | ||
| Loss, before tax | -399,897 | -401,403 | ||
| Net loss | -399,897 | -401,403 | ||
| Net loss per share attributable to common stockholders, basic | -0.02 | -0.02 | ||
| Net loss per share attributable to common stockholders, diluted | -0.02 | -0.02 | ||
| Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic | 16,072,267 | 16,072,267 | ||
| Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, diluted | 16,072,267 | 16,072,267 | ||
Accustem Sciences Inc. (ACUT)
Accustem Sciences Inc. (ACUT)